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A B S T R A C T
Selective decontamination of the digestive tract (SDD) using combinations of oral non-absorbable
antibiotics has been proposed as a means of preventing multidrug-resistant (MDR) infections. The
minimum inhibitory concentrations (MICs) of rifaximin (RIFAX) were determined against 262 Gram-
negative and Gram-positive bacterial isolates by broth microtitre assay. Rifampicin (RIF) was used as a
comparator in the analysis. Synergistic interactions between RIFAX and polymyxin B (PMB) were
assessed by using the chequerboard method and calculating the fractional inhibitory concentration
index (FICI). The antimicrobial activities of both RIFAX and RIF were similar with little variation in the
overall MIC distributions for Gram-negative non-fermenters and Gram-positive bacteria. However,
against Enterobacteriaceae higher MICs (>16 mg/L) were observed for RIFAX than for RIF (50% vs 27%).
Amongst the 262 isolates tested, 100 could be considered resistant to RIFAX. Overall, the combination of
RIFAX and PMB was more active against all of the isolates tested compared with either drug alone, with
reductions of 2–11 doubling dilutions in individual MICs. Potent synergy was observed with the
RIFAX + PMB combination using FICI criteria (FICI range 0.02–0.5). The data presented here suggest that
combination therapy may be signiﬁcantly more effective against isolates with RIFAX and/or PMB
resistance and could be considered as part of a SDD regimen aimed at reducing enteric carriage of MDR
pathogens in colonised and infected patients.
 2015 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All
rights reserved.
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Many bacterial infections arise endogenously from the normal
ﬂora of the gastrointestinal tract. Acquisition and colonisation of
the human gut by multidrug-resistant (MDR) strains either in
hospitals, through travel, due to antibiotic exposure or in early life
may have signiﬁcant implications for treatment. Selective decon-
tamination of the digestive tract (SDD) using combinations of oral
non-absorbable antibiotics has been proposed as a means of
preventing MDR infections [1]. A systematic review concluded that
the use of SDD can reduce the incidence of respiratory tract* Corresponding author. Present address: Centre for Immunobiology, Queen
Mary, University of London, 4 Newark Street, Whitechapel, London E1 2AT, UK.
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0933-3657/$ – see front matter2213-7165/ 2015 International Society for Chemotheinfections as well as overall in-hospital mortality [2]. Pooled data
from 36 clinical trials involving 6914 patients demonstrated that
both systemic and topical regimens reduce the rate of respiratory
tract infections and lower mortality in patients receiving
treatment in intensive care units (ICUs). Other evidence suggests
that SDD regimens have the potential to prevent between 2000 and
3000 deaths per annum in individuals hospitalised in the UK alone
[3].
Although a number of antimicrobials have been used in SDD
trials (polymyxins, glycopeptides, aminoglycosides, amphotericin),
there is little consensus on the optimum combination of drugs to
use, particularly in individuals colonised with MDR strains. There is
a need to identify a regimen that may be effective against those
colonised with bacteria belonging to the ESKAPE group of
pathogens (Enterobacter, Staphylococcus aureus, Klebsiella, Acineto-
bacter baumannii, Pseudomonas aeruginosa, Enterococcus) [4]. Theserapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.
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and display high levels of antimicrobial resistance, including the
production extended-spectrum b-lactamases (ESBLs) and resis-
tance to carbapenems [5].
Rifaximin (RIFAX) is a semisynthetic rifamycin derivative. It is
poorly absorbed in the human gut and is licensed to treat travel-
associated diarrhoea due to enterotoxigenic strains of Escherichia
coli and other enteric pathogens [6]. It is effective in reducing
bacterial overgrowth in the small intestine [7] and has also been
used successfully in the treatment of Clostridium difﬁcile infection
[8]. It has orphan drug status in the adjunctive treatment of hepatic
encephalopathy [7].
Polymyxins, which have activity primarily against Gram-
negative bacteria, are also poorly absorbed and have been used
in SDD regimens [9]. In SDD, polymyxin E (colistin) in combination
with either oral gentamicin or neomycin has been shown to be
effective in the eradication of ESBL-producing Enterobacteriaceae
and carbapenem-resistant Klebsiella pneumoniae [10,11] from
colonised patients. There is also evidence that polymyxins
signiﬁcantly enhance the activity of other antimicrobials that
have little or no activity alone. Colistin combined with rifampicin
(RIF) has also been proposed as a combination therapy for the
treatment of systemic MDR A. baumannii and P. aeruginosa
infections [12,13].
In this study, we investigated the in vitro activity of RIFAX
combined with polymyxin B (PMB) against a diverse collection of
strains that would need to be targeted in any regimen based on
exploiting the properties of these drugs in any future SDD therapy
aimed at tackling the problem of MDR bacteria.
2. Methods
2.1. Bacterial isolates, antimicrobials and media
Bacterial type strains were obtained from the National
Collection of Type Cultures (NCTC), Public Health England
(Colindale, UK). Clinical isolates were sourced from Barts Health
NHS Trust (London, UK) and the existing collection held at Queen
Mary University London (Antimicrobial Research Group). Staphy-
lococcus aureus strains with reduced susceptibility to glycopep-
tides (GISA) were obtained from the Network for Antimicrobial
Resistance on Staphylococcus aureus (Network for Antimicrobial
Resistance in Staphylococcus aureus, USA). Identiﬁcation and
routine susceptibility testing of clinical isolates was performed
according to standard laboratory protocols. RIFAX was purchased
from Santa Cruz Biotechnology Inc. (Heidelberg, Germany),
polymyxin B sulphate was from VWR International Ltd. (Leighton
Buzzard, UK) and RIF was from Sigma–Aldrich (Dorset, UK).
All bacterial culture media were sourced from Oxoid Ltd.
(Basingstoke, UK) or Sigma–Aldrich.
2.2. Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) of RIFAX were
assessed by broth microdilution (BMD) assay in cation-adjusted
Mueller–Hinton II broth (CA-MHB) according to European Commit-
tee on Antimicrobial Susceptibility Testing (EUCAST) guidelines
[14]. The MIC of RIFAX was determined against 262 bacterial
isolates, including 200 Gram-negative isolates [E. coli, n = 27;
K. pneumoniae, n = 38; miscellaneous Enterobacteriaceae (Serratia
marcescens, Enterobacter cloacae, Enterobacter aerogenes, Morganella
spp. and Citrobacter spp.), n = 35; A. baumannii, n = 36; Stenotropho-
monas maltophilia, n = 32; and P. aeruginosa, n = 32] and 62 Gram-
positive bacterial strains [S. aureus (meticillin-susceptible S. aureus,
meticillin-resistant S. aureus (MRSA) and vancomycin-intermediate-
resistant S. aureus), n = 28; Streptococcus spp. (Streptococcuspyogenes, Streptococcus agalactiae and Streptococcus sanguinis),
n = 9; Enterococcus faecalis and glycopeptide-resistant E. faecium,
n = 25].
As no clinical breakpoints have been proposed by either EUCAST
or the Clinical Laboratory Standards Institute (CLSI) to infer
susceptibility to RIFAX, the MIC of RIF was also determined for each
isolate and was used as a comparator in the analysis of RIFAX MIC
distributions.
2.3. Rifaximin and polymyxin B synergy studies
The potential for synergy between RIFAX and PMB was
investigated against 31 type strains and MDR isolates with deﬁned
mechanisms of resistance, including E. coli, K. pneumoniae, A.
baumannii, S. marcescens, S. maltophilia, P. aeruginosa, E. cloacae and
E. aerogenes producing KPC, VIM-2/4, NDM and OXA-23/48/181
carbapenemases, S. aureus (mecA/vraSR) and enterococcal isolates
(vanA/B) with meticillin resistance and reduced susceptibility to
glycopeptides, and antibiotic-susceptible strains of S. pyogenes
(Table 1).
Activity of the RIFAX + PMB combination was then assessed in
chequerboard assays by BMD in CA-MHB. The MICs of each drug
alone and in combination were recorded and interactions were
assessed by calculation of the fractional inhibitory concentration
index (FICI) [15]. An FICI of 0.5 was deﬁned as synergy, FICIs of
>0.5 to 4.0 were deemed intermediate/additive, and an FICI of
>4.0 was considered antagonistic.
As there are no established breakpoints for deﬁning suscepti-
bility to RIFAX, a breakpoint value of 16 mg/L suggested by the
French Society for Microbiology (SFM) [16] for determining
susceptibility/resistance of Acinetobacter spp. to RIF was used in
the interpretation of MICs. For Gram-positive bacteria, the EUCAST
RIF staphylococcal/streptococcal species-speciﬁc breakpoint of
MIC  0.06 mg/L [14] was used to infer susceptibility. The EUCAST
breakpoint of 2 mg/L for colistin sulfate was used in the
interpretation of susceptibility to PMB for all Enterobacteriaceae
and other Gram-negative species [14].
3. Results and discussion
The antimicrobial activities of RIFAX and RIF were similar with
little variation in the overall MIC distributions for Gram-negative
non-fermenters (GNNFs) and Gram-positive bacteria (Figs. 1 and
2). However, against Enterobacteriaceae higher MICs (>16 mg/L)
were observed for RIFAX than for RIF (50% vs 27%). Amongst the
262 isolates tested, 100 could be considered resistant to RIFAX
(GNNFs, n = 23; Enterobacteriaceae, n = 50; and Gram-positives,
n = 27) based on the breakpoints for A. baumannii [16], S. aureus
and Streptococcus spp. [14].
Analysis of MIC distributions revealed that the majority of
GNNFs (Fig. 2) had a RIFAX MIC between 1 mg/L and 16 mg/L. This
is comparable with current data on the antimicrobial activity of RIF
against A. baumannii [17]. Both MIC50 and MIC90 values were
lowest for S. maltophilia isolates (RIF/RIFAX MIC50 = 8/8 mg/L,
MIC90 = 16/64 mg/L). The MIC ranges for P. aeruginosa (RIF/RIFAX
MIC50 = 16/16 mg/L, MIC90 = 32/128 mg/L) were narrower than
those for A. baumannii (RIF/RIFAX MIC50 = 2/1 mg/L, MIC90 = 256/
256 mg/L).
Against Enterobacteriaceae, the MIC distribution was narrower
than that observed with GNNFs, with the majority of strains
requiring 4–256 mg/L (RIF/RIFAX MIC50 = 16/16 mg/L, MIC90 = 32/
256 mg/L). This is not surprising as resistance to both RIF and
RIFAX has been previously reported in E. coli owing to
chromosomal mutations in rpoB and active efﬂux of the antibiotic
[18,19].
Table 1
Minimum inhibitory concentrations (MICs) of rifaximin (RIFAX) and polymyxin B (PMB) alone and in combination, and fractional inhibitory concentration indices (FICIs) for
important potential pathogens of the human gut (n = 31).
Isolate Characteristics MIC alone (mg/L) MIC in combination
(mg/L)
FICI
RIFAX PMB RIFAX PMB
Escherichia coli 12241 NCTC type strain 4 0.5 0.13 0.06 0.16
E. coli EC98 (2014) VIM-4 producer (ST131) 32 0.06 8 0.03 0.75
E. coli EC172 (2014) OXA-181 producer (ST410) 64 0.13 0.13 0.03 0.25
E. coli EC204 NDM-1 producer 32 0.13 0.25 0.03 0.26
Klebsiella pneumoniae 9633 NCTC type strain 8 0.25 0.5 0.06 0.31
K. pneumoniae KP7 KPC-2 producer (ST258) 128 0.25 2 0.03 0.14
K. pneumoniae KP50 NDM-1 producer 256 0.25 16 0.03 0.19
K. pneumoniae KP52 OXA-48 producer 64 0.25 1 0.03 0.14
Enterobacter aerogenes 9735 NCTC type strain 8 0.5 2 0.03 0.31
E. aerogenes EA1 CTX-M-1, hAmpC and PL 8 0.13 2 0.03 0.5
E. aerogenes EA2 ESBL: CTX-M-1 producer 16 0.13 2 0.03 0.38
Enterobacter cloacae 13380 NCTC type strain 128 0.25 0.5 0.06 0.25
E. cloacae Encl102 VIM-4 producer 128 0.13 4 0.03 0.28
Serratia marcescens 13382 NCTC type strain 32 128 0.5 0.06 0.02
S. marcescens 156 NDM-1 producer 128 128 2 0.5 0.02
Pseudomonas aeruginosa 27853 ATCC type strain 32 0.5 2 0.06 0.19
P. aeruginosa PA30 VIM-2 producer 32 0.5 8 0.13 0.5
Acinetobacter baumannii 19606 ATCC type strain 2 0.25 0.5 0.06 0.5
A. baumannii AB12 MDR: hAmpC producer (UK South East clone) 4 0.13 0.13 0.03 0.28
A. baumannii AB14 OXA-23 producer (UK OXA-23 clone 1) 8 0.25 2 0.03 0.38
A. baumannii AB306 NDM-1 producer 1 0.25 0.13 0.03 0.25
Stenotrophomonas maltophilia 10258 NCTC type strain 32 0.25 0.13 0.06 0.25
S. maltophilia SMB02 MDR clinical isolate 32 1 0.13 0.03 0.03
Staphylococcus aureus 12493 MRSA (mecA) 0.02 128 0.004 0.5 0.26
S. aureus 25923 ATCC type strain 0.06 64 0.015 0.03 0.24
S. aureus Mu50 GISA (vraSR) 128 128 0.5 16 0.13
Enterococcus faecalis 29212 ATCC type strain 2 64 0.5 1 0.27
Enterococcus faecium OEF42 GRE 16 128 4 0.06 0.25
E. faecium OEF65 GRE 64 128 16 32 0.38
Streptococcus pyogenes SPY1 Clinical isolate 0.06 8 0.008 0.5 0.19
S. pyogenes SPY2 Clinical isolate 0.03 16 0.008 0.03 0.25
NCTC, National Collection of Type Cultures; hAmpC, hyperproduction of chromosomal AmpC; PL, porin loss; ESBL, extended-spectrum b-lactamase; ATCC, American Type
Culture Collection; MDR, multidrug-resistant; MRSA, meticillin-resistant S. aureus; GISA, glycopeptide-intermediate-resistant S. aureus; GRE, glycopeptide-resistant
Enterococcus.
Fig. 1. Distribution of rifampicin minimum inhibitory concentrations against Gram-positive, Enterobacteriaceae and non-fermenting isolates.
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two populations could be deﬁned. One group contained the
streptococcal and S. aureus type strains (RIF/RIFAX MIC = 0.00375–
0.063 mg/L), comparable with existing EUCAST data for RIF
[17]. The second group had MICs ranging from 1 to 128 mg/L
and contained the enterococcal (RIF/RIFAX MIC50 = 64/64 mg/L,
MIC90 = 128/128 mg/L), GISA and clinical MRSA isolates.Of the 31 isolates assessed in the chequerboard analysis,
16 were considered resistant to RIFAX (MIC > 16 mg/L) and 9 were
considered resistant to PMB (MIC > 2 mg/L). These included all
of the S. marcescens, S. aureus and Enterococcus spp. and one
S. pyogenes isolate (Table 1). Surprisingly, both S. pyogenes isolates
appeared relatively susceptible to PMB. Although polymyxins are
thought to have no therapeutic utility in the treatment of
Fig. 2. Distribution of rifaximin minimum inhibitory concentrations against Gram-positive, Enterobacteriaceae and non-fermenting isolates.
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disrupt the integrity of the ExPortal protein secretion organelle in
streptococci, rendering them susceptible to killing [20].
Overall, the combination of RIFAX + PMB was more active
against all of the isolates tested compared with either drug alone,
with reductions of 2–11 doubling dilutions in individual MICs.
With the exception of a single VIM-4-producing strain of E. coli
(FICI = 0.75), the RIFAX + PMB combination resulted in potent
synergy using FICI criteria (FICI range 0.02–0.5).
Concentrations of both drugs required for synergy to be
preserved in vivo are likely to be achievable in an oral SDD
regimen. RIFAX concentrations of 4–8 mg/g of stool have been
measured in the gut following oral administration, without
toxicity [21,22]. The combination of RIFAX + PMB could therefore
still be a viable option for decolonisation therapy, even when
signiﬁcant synergy is not observed with the drugs in combination.
A recent analysis of the cost effectiveness of SDD regimens for
patients in ICUs found that SDD was beneﬁcial in reducing length
of patient stay and treatment costs by as much as s1508 per
patient [23].
The results of this study support previous work with RIF and
colistin suggesting a role in the treatment of E. coli, P. aeruginosa
and S. maltophilia infections [24,25]. Although RIFAX alone has
been shown previously to be effective in gut decolonisation [7], the
data presented here suggest that combination therapy may be
signiﬁcantly more effective against isolates with RIFAX and/or PMB
resistance. Combinations of licensed non-absorbable agents are
seldom used systemically and could be considered as part of a SDD
regimen aimed at reducing enteric carriage of MDR pathogens in
colonised and infected patients.
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